Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
Nucleic Acids Res. 2011 Oct;39(19):8392-403. doi: 10.1093/nar/gkr458. Epub 2011 Jul 14.
Pregnane X receptor (PXR), acting as a xenobiotic-activated transcription factor, regulates the hepatic metabolism of therapeutics as well as endobiotics such as steroid hormones. Given our finding that PXR activation by rifampicin (RIF) represses the estrogen sulfotransferase (SULT1E1) gene in human primary hepatocytes and hepatocellular carcinoma Huh7 cells, here we have investigated the molecular mechanism of this repression. First the PXR-responsive enhancer was delineated to a 100 bp sequence (-1000/-901), which contains three half sites that constitute the overlapping direct repeat 1 (DR1) and direct repeat 2 (DR2) motifs and two forkhead factor binding sites. siRNA knockdown, chromatin immunoprecipitation and chromatin conformation capture assays were employed to demonstrate that hepatocyte nuclear factor 4α (HNF4α) bound to the PXR-responsive enhancer, and activated the enhancer by looping its position close to the proximal promoter. Upon activation by RIF, PXR indirectly interacted with the enhancer, decreasing the interaction with HNF4α and dissolving the looped SULT1E1 promoter with deacetylation of histone 3. Removal of the DR sites from the enhancer hampers the ability of HNF4α to loop the promoter and that of PXR to repress the promoter activity. Thus, PXR represses human SULT1E1, possibly attenuating the inactivation of estrogen.
孕烷 X 受体 (PXR) 作为一种外源物质激活的转录因子,调节治疗药物以及内源性物质(如甾体激素)的肝脏代谢。鉴于我们发现利福平 (RIF) 激活 PXR 会抑制人原代肝细胞和肝癌 Huh7 细胞中的雌激素磺基转移酶 (SULT1E1) 基因,我们在此研究了这种抑制的分子机制。首先,我们将 PXR 反应增强子划定为 100bp 序列(-1000/-901),其中包含三个半位点,构成重叠的直接重复 1 (DR1) 和直接重复 2 (DR2) 基序以及两个叉头因子结合位点。siRNA 敲低、染色质免疫沉淀和染色质构象捕获实验表明,肝细胞核因子 4α (HNF4α) 与 PXR 反应增强子结合,并通过将其位置靠近近端启动子来激活增强子。在 RIF 激活后,PXR 间接与增强子相互作用,减少与 HNF4α 的相互作用,并通过组蛋白 3 的去乙酰化溶解与 SULT1E1 启动子形成的环。从增强子中去除 DR 位点会削弱 HNF4α 形成环的能力,以及 PXR 抑制启动子活性的能力。因此,PXR 抑制人 SULT1E1,可能会减弱雌激素的失活。